CTOR News and Press, Citius Oncology Inc.

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers PR Newswire Study data from patients with relapsed or refractory gynecologic cancer...

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma PR Newswire Topline data of investigator‑initiated study at the Universit...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The FDA issued more than 50 oncology approvals in 2025, with most of those concentrated in immunotherapy and targeted therapy, and January 2026 extended that pace with Breakthroug...

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J. ...

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J. , Feb....

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar PR Newswire Third international distribution agreement further advances global access strategy with major markets in Europe CRANFORD, N.J. , Feb. 11,...

How $594B in Precision Tech is Cracking the Metastatic Cancer Code Canada NewsWire Issued on behalf of Oncolytics Biotech Inc.   USANewsGroup.com   News Commentary VANCOUVER, BC , Jan. 7, 2026 /CNW/ -- The global cancer drugs market is surging toward $59...

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private place...

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules PR Newswire CRANFORD, N.J. , Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: ...

2025-12-09 10:57:40 ET More on Citius Oncology Citius Oncology announces $18 million registered direct offering Seeking Alpha’s Quant Rating on Citius Oncology Historical earnings data for Citius Oncology Financial information for Citius Oncology ...